Paul Mischel

Prof. Paul Mischel is is a Professor of Pathology and an Institute Scholar at Sarafan ChEM-H at Stanford University. Dr. Mischel is a physician scientist trained in pathology and cancer biologylab has made a series of discoveries published in Nature, Science, and Nature Genetics, that have identified a central role for ecDNA (extrachromosomal DNA) in cancer development, progression, accelerated tumor evolution and drug resistance. These findings have provided a new understanding of the fundamental mechanisms of oncogene amplification and the spatial organization of altered tumor genomes, launching a new area of cancer research that links circular architecture with tumor pathogenesis. He leads Team eDyNAmiC, which was awarded one of the $25M Cancer Grand Challenges Awards from CRUK and the National Cancer Institute, to tackle the extrachromosomal DNA grand challenge. His lab’s discoveries have resulted in new understandings of some of the fundamental processes by which oncogene amplification drives cancer progression and drug resistance and pointed that way towards new treatments that are being developed. He is a scientific co-founder of Boundless Bio, which develops ecDNA-directed therapies for patients with oncogene-amplified cancers.